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Review
Biologic Treatments for Sports
Injuries II Think Tank—Current
Concepts, Future Research, and
Barriers to Advancement, Part 2
Rotator Cuff
Iain R. Murray,* MD, PhD, Robert F. LaPrade,‡** MD, PhD, Volker Musahl,§ MD,
Andrew G. Geeslin,|| MD, Jason P. Zlotnicki,§ MD, Barton J. Mann,†{ PhD,
and Frank A. Petrigliano,# MD
Investigation performed at Steadman Philippon Research Institute, Vail, Colorado, USA
Rotator cuff tears are common and result in considerable morbidity. Tears within the tendon substance or at its insertion into the
humeral head represent a considerable clinical challenge because of the hostile local environment that precludes healing. Tears
often progress without intervention, and current surgical treatments are inadequate. Although surgical implants, instrumentation,
and techniques have improved, healing rates have not improved, and a high failure rate remains for large and massive rotator cuff
tears. The use of biologic adjuvants that contribute to a regenerative microenvironment have great potential for improving healing
rates and function after surgery. This article presents a review of current and emerging biologic approaches to augment rotator cuff
tendon and muscle regeneration focusing on the scientific rationale, preclinical, and clinical evidence for efficacy, areas for future
research, and current barriers to advancement and implementation.
Keywords: biologic healing enhancement; biology of tendon; growth factors/healing enhancement; rotator cuff; stem cell therapy;
tendinosis
Rotator cuff disease accounts for over 4.5 million physician
visits per year, with over 250,000 repairs performed annu-
ally in the United States.30,139 Cadaveric studies have
revealed a 6% incidence of full-thickness rotator cuff tears
in those aged <60 years, which rises to 30% in those aged
>60 years.77 For many patients, these injuries result in
considerable disability, pain, and a diminished quality of
life.38 Current standard surgical treatment involves open
or arthroscopic repair of the torn tendon(s) frequently using
suture anchors in a variety of configurations.86 However,
considerable variation in surgical procedures exists, con-
firming the lack of a single reliable technique.86 Despite
improvements in pain and function after rotator cuff
repair, the rate of persistent tears has been reported from
11% to 94%, and it is recognized that current surgical
treatments need improvement.40,43 In this review article,
we outline the pathogenesis of rotator cuff tears outlining
current and emerging biological approaches that aim to
improve healing and function after surgical repair. In
addition, we discuss critical areas for future research and
barriers to the advancement and implementation of
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biologic therapies for the rotator cuff, identified at the
2015 American Orthopaedic Society for Sports Medicine
(AOSSM) Biologics II Think Tank.1
PATHOGENESIS OF ROTATOR CUFF TEARS
The pathogenesis of rotator cuff tendon tears is multifacto-
rial but can be broadly considered as resulting from chronic
degeneration, trauma, or a combination of these factors.
Chronic degeneration can occur through extrinsic impinge-
ment from bony structures surrounding the cuff and degen-
eration within the tendon itself where tensile loads exceed
intrinsic healing and adaptive responses. Repetitive micro-
trauma is commonly seen in overhead or throwing athletes
while acute avulsions of the rotator cuff are associated with
contact sports or trauma.14
Biologic approaches target a particular aspect of the
injury microenvironment. An appreciation of the normal
healing response allows clinicians to identify which strat-
egy may be of greatest benefit for individual patients. The
rotator cuff tendon is composed primarily of type I collagen
produced by tissue-specific fibroblasts called tenocytes.125
Rotator cuff muscle is highly vascular but the size and num-
ber of vessels progressively decrease within the tendinous
region and in proximity to the humeral head insertion.17 At
the site of insertion into the proximal humerus, there is a
transition into 4 distinct tissue zones: tendon, nonminera-
lized fibrocartilage, mineralized fibrocartilage, and bone.6
This arrangement is critical to the ability of the rotator cuff
to withstand force. Tendon heals in 3 overlapping phases,
namely an inflammatory, proliferative (or fibroblastic), and
remodeling phase.125 Cells from both within and outside
the tendon contribute at each stage. The inflammatory
phase occurs over the 7 days after injury and is character-
ized by fibrin and fibronectin deposition by platelets.34,125
Platelets also release a host of growth factors, including
insulin-like growth factor–1 (IGF1), platelet-derived
growth factor (PDGF), and transforming growth factor–b
(TGFb), that attract macrophages and neutrophils.34
Macrophages secrete further TGFb, promoting activation
of myofibroblasts and the formation of scar tissue.
Mesenchymal stem cells (MSCs) capable of differentiating
into tenocytes and myofibroblasts are recruited to the
area.142 The proliferative stage begins within 48 hours and
lasts up to 6 weeks.125 In the remodeling phase, type III
collagen laid down initially is remodeled to type I collagen
resulting in a more organized matrix.34 Full-thickness
tears of the rotator cuff initiate a cascade of alterations that
compromise the entire muscle-tendon unit.45,46 In both
clinical and animal studies, changes in muscle architecture
and structure have been reported.45,46 After a rotator cuff
tear, fat accumulates within themuscle, which itself under-
goes atrophy.69 Tendomuscular retraction and muscle
fibrosis result, creating tension over the site of injury, fur-
ther compromising healing potential.46
Animal studies have confirmed that the healing tendon-
bone insertion after rotator cuff repair does not resemble
the native enthesis.19 Instead of the 4 transitioning zones,
the repaired tendon forms fibrovascular scar tissue with a
large proportion of type III collagen rather than the biome-
chanically superior type I collagen.74 In particular, the zone
of calcified cartilage does not reform, and this scar tissue is
biomechanically weaker and more prone to failure than the
native insertion.74
A HOSTILE ENVIRONMENT FOR HEALING
Studies have identified biological factors that are key deter-
minants of failure after rotator cuff repair, including intrin-
sic tendon degeneration, muscle degeneration, fatty
infiltration, and a lack of vascularity. These studies high-
light the unique challenges of tissue healing and regenera-
tion at the rotator cuff tendon and its enthesis.
Limited Blood Supply
The vascularity of rotator cuff tendon at the anterolateral
rotator cuff is significantly lower than that at the bony
insertion, limiting a meaningful inflammatory response
and access to extrinsic progenitors.13 Although no studies
have directly proven a causal relationship between
increased vascularity and improved rotator cuff healing,
emerging data suggest that stimulating angiogenesis may
improve tensile strength of Achilles tendons after repair.150
Absence of Appropriate Signals Directing
MSC Recruitment and Differentiation
An absence of appropriate molecular signals to direct cell
differentiation at the zone of injury has been theorized to
contribute to the formation of biomechanically inferior
fibrotic tissue, although this is not currently substantiated
by robust evidence.50,74,111 This is the rationale for strate-
gies that aim to direct healing away from scar formation
toward the regeneration of a native tendon-bone insertion
site through the application of growth factors that stimu-
late tenocyte and bone differentiation.
Local MSC Population Depleted in Patients
With Rotator Cuff Tears
In a large study of 200 patients, Hernigou et al59 demon-
strated that the number of MSCs present in the greater
tuberosity of patients with a rotator cuff tear decreases as
a function of a number of clinical factors, including lag time
from tear onset to treatment, tear size, chronicity, and
degree of fatty infiltration, among others. Therefore,
patients in the greatest need of successful repair are the
ones who are poorest equipped to heal.
Intra-articular Location of Rotator Cuff
Limits Inflammatory and Proliferative Response
Synovial fluid with its fibrinolytic enzymes prohibits the
formation of a blood clot, which subsequently leads to a lack
of provisional scaffold bridging the wound site.101
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Tension Over the Healing Site
Tension over the rotator cuff repair prevents healing and
increases the risk of rerupture.40 Tear size and tenovascu-
lar retraction secondary to muscle atrophy and fibrosis both
contribute to this phenomenon.40
BIOLOGIC OPTIONS TO AUGMENT HEALING
Biologic adjuvants have great potential to improve rotator
cuff healing and reduce rates of reinjury. The ultimate goal
after rotator cuff injury is to re-create the native tendon
insertion site formed during embryologic development, and
as such, improve rotator cuff tendon healing while at the
same time diminishing, halting, or reversing fatty degen-
eration of the muscle. Current and emerging biological
approaches include the application of growth factors,
platelet-rich plasma (PRP), stem cells, and patches.
Growth Factors
Numerous cytokines and growth factors can be found in the
rotator cuff in predictable expression patterns early in the
healing process. These factors function primarily to promote
the inflammatory response/angiogenesis (vascular endothe-
lial growth factor [VEGF], basic fibroblast growth factor
[bFGF], PDGF); increase cellular proliferation, differentia-
tion, andmatrix synthesis (TGFb); promote bony incorpora-
tion of tendon (bone morphogentic protein [BMP]); and
remodel extracellular matrix (matrix metalloproteinase
[MMP]). While no human study investigating recombinant
growth factors in rotator cuff tendon healing has yet been
published, the results of animal studies indicate that deliv-
ery or modulation of growth factors may provide a useful
way of improving the biology of rotator cuff healing.61,134
Proinflammatory and Angiogenic Cytokines. Tendon
degeneration and tears frequently affect the most distal
hypovascular portions of the supraspinatus and infraspina-
tus tendons, close to their insertion sites, prompting some
investigators to suggest that the establishment of vascular-
ity at the tendon-bone interface may promote healing.133
However, there still remains a paucity of data to support
or refute this concept.
VEGF describes a family of signaling proteins that stimu-
late vasculogenesis through tyrosine kinase receptor–
mediated signaling cascades.103 No specific study has evalu-
atedVEGFaugmentationof rotator cuff repairs, althoughcon-
flictingresultshavebeenachieved inanimalmodelsofAchilles
tendon healing and anterior cruciate ligament (ACL) recon-
struction.148,150 Application of VEGF improved tendon tensile
strength in a ratmodel of Achilles tendon repair150 while ACL
grafts soaked in VEGF prior to implantation in a sheepmodel
of ACL repair resulted in increased graft laxity.148
Fibroblast growth factors (FGFs) act by stimulating prolif-
eration of capillary endothelial cells. In addition, they are
recognized to have a mitogenic effect on mesenchymal
cells.103 While both FGF1 and FGF2 (bFGF) are reported to
be present early within the rotator cuff repair process, basic
FGF is considered the more potent mitogen72,144 for
mesenchymal stem cells. Ide et al61 reported that FGF2,
when applied to repaired supraspinatus tears in rats, accel-
erated bone ingrowth resulting in improved biomechanical
properties and better histologic scores at 2 weeks compared
with controls.However, nodifferenceswere seenbetween the
control and experimental groupsat4and6weeks, suggesting
that FGF2 accelerated ingrowth but not the final result.61 In
a study examining the effects of FGF2 applied in an acellular
dermalmatrix, Ide et al62 demonstrated that FGF2 improved
histologic and strength scores comparedwith controls. These
studies support a possible role for FGF2 in accelerating and
remodeling the rotator cuff tendon repair site.61
PDGF is a proinflammatory cytokine important in rotator
cuff healing that peaks between 7 and 14 days after injury.72
PDGF exists in 3 dimeric isoforms: PDGF-AA, -BB, and -AB.
These isoforms function as chemotactic agents for inflamma-
tory cells andpromote type I collagen synthesis.Uggenet al134
examinedtheeffectsof recombinanthumanPDGF-BB–coated
suturesonrotator cuffhealing inasheepmodel.Theyreported
enhanced histological scores in animals receiving PDGF over
controls at 6 weeks, although there was no significant differ-
ence between the groups in terms of ultimate load to failure.
Hee at al57 reported that addition of recombinant human
PDGF-BB implanted in a type I collagen graft for rotator cuff
repair in sheep improved thebiomechanical strengthandana-
tomic appearance of healing tendons compared with controls.
Importantly, the responsewas dependent on the dose, timing,
and the PDGF delivery vehicle used. PDGF augmentation
holds promise for rotator cuff repair but further studies are
required to determine its efficacy.
Cytokines to Increase Cellular Proliferation,
Differentiation, and Extracellular Matrix Synthesis. The
TGFb superfamily of cytokines includes 3 isoforms (TGFb1,
TGFb2, and TGFb3) that have diverse physiologic effects,
including cellular proliferation, differentiation, and matrix
synthesis within the tendon.4 Postnatally, wound healing is
characterized by extensive scar tissue formation with high
levels of expressed TGFb1, while the wound microenviron-
ment in scarless fetal healing is characterized by high lev-
els of TGFb3.28 It has therefore been proposed that the
delivery of exogenous TGFb3 could promote regenerative
healing of a torn rotator cuff at the tendon-bone insertion
site.73 With this in mind, 3 recent studies have examined
the use of TGFb3 in a rat rotator cuff model. Kim et al70
investigated the role of TGFb1 and TGFb3 at the tendon-
bone insertion of repaired rat supraspinatus tendons. Ani-
mals receiving TGFb1 through an osmotic pump had
increased type III collagen production, consistent with a
scar-mediated healing response, and demonstrated a trend
toward reduced mechanical properties compared with con-
trols. TGFb3 delivery resulted in no histological or biome-
chanical advantage. Using a system that delivers TGFb3
directly to the tendon-bone insertion, the same authors
demonstrated accelerated healing in experimental animals
with increased inflammation, cellularity, vascularity, and
cell proliferation at early time points.82 In addition, signif-
icant improvements in structural and mechanical proper-
ties were demonstrated. Kovacevic et al73 examined the
delivery of TGFb3 in an injectable calcium-phosphate
matrix to the tendon-bone interface of repaired rat
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supraspinatus tendons. The addition of TGFb3 to the
matrix significantly improved strength at the repair site 4
weeks postoperatively. Overall, these findings suggest a
potential therapeutic role for TGFb3 in improving tendon
healing after surgical repair.
Osteoinductive Factors. Healing of the rotator cuff onto
the humerus is dependent on bone ingrowth into the repaired
tendon.115 It has therefore been hypothesized that osteoin-
ductive growth factors would improve rotator cuff tendon
healing. The BMPs belong to the TGFb superfamily and are
best known for their ability to stimulate bone formation,
although they also regulate fibrocartilage, neotendon, and
ligament formation.78CertainBMPs,namelyBMP1,BMP12,
BMP13, and BMP14, are expressed in the acute phase of
healing after rotator cuff tears144 while a number of BMPs
(including BMP2 and BMP7) have been reported to induce
collagen production when added to cultured tenocyte-like
cells derived fromsamples ofhumanrotator cuff.107 For these
reasons, the ability for BMPs to augment rotator cuff healing
is currently under investigation in preclinical studies.
Studies in sheep and rats have demonstrated that BMP
therapy is beneficial in rotator cuff repair.95,123 Murray
et al95 reported that delivery of BMP13 on a collagen sponge
improved the maximum loads to failure at 6 weeks after sur-
gery when compared with controls in a rat model of supraspi-
natus repair. At 6 weeks, BMP13-treated repairs had
recovered to 80% of the ‘‘strength to failure’’ of uninjured con-
trols. Application of recombinant human BMP12 alone in a
collagen or hyaluronic acid sponge strengthened the repair
and accelerated healing in an ovine model of rotator cuff
repair.123 In these studies, BMP12 and BMP13 improved the
strength andhistological appearance of repaired tendonswith
improved cellular organization and fiber alignment. Dines
et al31 reported that coating of sutures with recombinant
BMP14 accelerated tendon healing and enhanced strength.
However, no biomechanical or histologic difference was found
when compared with controls at 6 weeks. Rodeo et al115
reported thatacombinationofgrowthfactors (BMP2toBMP7,
TGFb1 to TGFb3, and FGF) within an osteoinductive bone
protein extract placed on the tendon-bone interface resulted
in stronger repairs, illustrated by greater load to failure at 12
weeks. However, when the loads were normalized for tissue
volume, no differences between treated and untreated
shoulders were found, whichmay suggest that the bovine cor-
tical bone extract may have accelerated the healing process
without improving repair quality. Similar results were
observedwithadditionofrecombinanthumanBMP12toacute
full-thickness tears in sheep.123 These findings suggest a
potential therapeutic role for osteoinductive factors in improv-
ing tendon-bone healing after surgical rotator cuff repair.
Regulators of Extracellular Matrix. A dynamic balance
between MMPs and their inhibitors (tissue inhibitors of
metalloproteinases [TIMPs])maintains the integrityof tissue
extracellular matrix.16 Dysregulation of this homeostasis
with elevated levels of MMPs is associated with tendon
degeneration and rupture.113 Elevated levels of MMP1 and
MMP3 have been demonstrated in the synovial fluid of
patients with massive rotator cuff tears.147 Furthermore,
McDowell et al85 demonstrated that MMP-mediated tissue
degradationwithin the immediate postoperative period after
a surgical repair leads toweakening of the rotator cuff tendon
at the repair site. As such, the possibility that selective inhi-
bition of MMPs may have a positive effect on tendon healing
has recently been explored. In addition to its antibiotic effect,
doxycycline is a potent MMP inhibitor that acts by competi-
tive binding of the zinc binding site of MMP enzyme and by
reducingMMPgene transcription.106Usinga ratmodel,Bedi
et al10 demonstrated that doxycycline-mediated inhibition of
MMP13activity after acute rotator cuff repairwas associated
with improved biomechanical and histological parameters of
healing at the tendon-bone interface.
Targeted Areas for Future Research and Barriers to
Advancement and Implementation. There is currently
strong rationale and preliminary evidence to support a
potential therapeutic role for growth factors after rotator
cuff repair. However, within reported studies there is con-
siderable variation in the preparation of growth factors
(recombinant, synthetic), delivery methods (local injection,
systemic dosing, within scaffold, coated sutures), timing
(preoperatively, perioperatively, postoperative, and
repeated dosing), and dose precluding comparison between
studies. This is further complicated by potential interactions
of these factors; for example, growth factors are rapidly
cleared after local injection, but their persistence may be
prolonged using scaffolds or coated suture material.32 The
optimal delivery method, timing, and dose will be different
for each growth factor given the unique expression patterns
of factors in normal healing and has not been explored in
these studies. There is a danger that conclusions on the
potential benefit of each growth factor are not supported
by studies that explore each of these specific factors.
In vivo, growth factors work in concert and synergisti-
cally to create appropriate bone-tendon healing, and it is
therefore intuitive that the most striking improvements in
rotator cuff repair will be achieved through the delivery of
multiple growth factors rather than by single growth factors
in isolation. A number of preliminary preclinical studies sup-
port this notion.56,121 In an in vitro model using rabbit flexor
digitorum tenocytes, the greatest cell proliferation rates
were achieved by combining bFGF, IGF1, and PDGF. This
combination was more effective at lower doses than when
the growth factors were delivered singly.27 This is likely to
vary depending on whether the repair involves tendon-bone
healing or only tendon-tendon. Finally, the combination of
growth factors may need to be individualized to the charac-
teristics of each tear; for example, a tear with considerable
bony avulsion may benefit from more osteoinductive cyto-
kines than a midsubstance tendon tear. The design of stud-
ies that reflect the complexities of rotator cuff healing is an
ongoing challenge. Critical areas for future research and
barriers to advancement of growth factor–based therapies
to treat rotator cuff injuries are summarized in Table 1.
Platelet-Rich Plasma
The use of PRP as a biological adjuvant to improve rotator
cuff tendon healing has recently gained popularity.89 Phy-
siological tendon healing involves a complex interaction of
cytokines, with some authors suggesting that no single
growth factor is likely to be effective when delivered in
4 Murray et al The Orthopaedic Journal of Sports Medicine
 at The University of Edinburgh on June 8, 2016ojs.sagepub.comDownloaded from 
isolation. PRP is a term used to describe preparations of
whole blood enriched for platelets that, once activated,
release a host of growth factors that may contribute to tis-
sue repair.3 Growth factors released by platelets are recog-
nized to perform a wide range of regenerative functions
including the proliferation and recruitment of stem cells,
modulation of local inflammatory responses, and stimula-
tion of new blood vessel formation.55 A number of these
growth factors have been shown to increase rotator cuff–
derived tenocyte proliferation and promote the production
of key extracellular matrix proteins including collagen
types I, II, and X; decorin; aggrecan; and biglycan.65 In
addition, PRP provides protection against oxidative stress
that can lead to cell apoptosis after injury118 and inhibits
the inflammatory effects of interleukin-1b (IL1b), which
contributes to rotator cuff tendon degeneration. Conver-
sely, TGFb present in PRP positively contributes to rotator
cuff tendon repair strength.100 Similarly, neotendon forma-
tion may be induced by cytokines present within PRP
including VEGF, PDGF, FGF2, TGFb, IGF1, and BMP2.2
PRP may enhance the self-healing potential of tissues by
recruiting and activating resident progenitors.63
Unfortunately, the use of PRP as an aid in arthroscopic
repair of the rotator cuff has not met the expectations
raised by in vitro studies.65 Clinical trials using different
autologous PRP formulations to augment rotator cuff tear
repairs have yielded controversial results.5,110,114,117
Appraisal of the literature is complicated by the range of
treated injuries, varying from small single-tendon tears to
massive multitendon tears; concomitant use of acromio-
plasty or not; and the formulation of PRP used, which
ranges from intratendon injection,67 spray application,110
or incorporation of a platelet-rich fibrin matrix into the
tendon repair site.20 A summary of level 1 studies evaluat-
ing the role of PRP to augment surgical repair is shown in
Table 2. Recent analyses evaluating all but 1 of the rando-
mized controlled trials to date have reported that there was
no significant difference in the rate of persistent tears
between a PRP and control group.21,111 However, stratified
analysis of small or medium lesions showed a significantly
lower persistent tear rate in the PRP group. Importantly,
the use of PRP appears safe, with only 2 cases of infection
and no complications reported in this meta-analysis.111
Further prospective randomized controlled trials (level 1
evidence) are necessary to establish whether PRP has a role
in the management of rotator cuff tears.
Targeted Areas for Future Research and Barriers to
Advancement and Implementation. There is growing inter-
est in establishing the optimal PRP formulation for rotator
cuff healing. The most effective platelet and leukocyte counts
and thebalancebetween these counts, aswell as the ratiowith
respect to plasma proteins, is not known. In particular, there
is debate about which factor(s) are central to the regenerative
effects of each formulation.While studies have indicated opti-
mumplatelet concentrations for bone regeneration (1,000,000
platelets/mm3),143 there is currently no consensus about the
bestplatelet concentration for rotator cuffhealingandnocom-
parative clinical study. In an in vitro study with tenocytes, Jo
et al65 showed that a concentration of 4,000,000 to 8,000,000
platelets/mm3 promotes higher cell proliferation. Different
platelet-leukocyte ratios show a plateau effect of platelet con-
centrations,with increasingplatelet concentrationsbeingdet-
rimental to extracellular matrix synthesis.15 There is
evidence to support that growth factors and cytokine concen-
trations are influenced by the cellular composition of PRP,
with leukocytes increasing catabolic signaling molecules.131
Increasing the platelet concentration within leukocyte-rich
PRP preparations results in the delivery of more anabolic
growth factors and decreased proinflammatory cytokines, but
the biological effect on tendons is diminished metabolism, as
indicatedbyadecrease in thesynthesisofbothcollagentypes I
and III.15 Together, this information suggests that minimiz-
ing leukocytes in PRP is more important than maximizing
platelet numbers with respect to decreasing inflammation
and enhancing anabolic signaling. However, other studies
have pointed out the positive role of leukocytes in PRP as
anti-infectious and immune regulatory agents.92 Dragoo
et al33 reported that leukocyte-rich PRP led to an inflam-
matory response, although the clinical implications of this
remains unclear. Three studies used leukocyte-rich PRP,
with better results,110 worse results,53 or no difference in
thePRP group.23Most clinical studies have used numerous
different PRP formulations. The obtained results have
never been analyzed to establish the influence of variable
leukocyte content. Further randomized controlled trials
comparing the effectiveness of leukocyte-rich PRP versus
purePRPwill help in defining the optimal PRP formulation
to manage rotator cuff injuries.
TABLE 1
Use of Growth Factors for Rotator Cuff Healing
Targeted Areas for Future Research Barriers to Advancement and Implementation
 Establish growth factors with greatest therapeutic potential
in rotator cuff healing
 Optimal preparation (synthetic/recombinant)
 Optimal delivery method (local injection/systemic dosing/
scaffold/coated sutures)
 Optimal timing of delivery
 Optimal dosing (including repeated dosing)
 Does tear location (tendon substance/avulsion) influence
choice of growth factor?
 Optimal combinations of growth factors
 Variation in growth factor preparation, delivery methods,
timing, and dosing precluding comparison between studies
 Models of rotator cuff tendon injury with sufficiently sensitive
imaging to detect differences in clinical outcomes
 Lack of sufficient experimental detail in published reports
The Orthopaedic Journal of Sports Medicine Biologic Treatments for Rotator Cuff Pathology 5
 at The University of Edinburgh on June 8, 2016ojs.sagepub.comDownloaded from 
Similarly, no comparative study has evaluated the use of
thrombin to activate the coagulation cascade in humans
despite authors setting out arguments for137 and against120
this option. Virchenko et al137 reported that the use of
thrombin leads to improved outcomes in a biomechanical
study in rat calcaneus tendons, while Scherer et al120
demonstrated that PRP without thrombin achieved better
results in the repair of skin defects.
A further variable affecting the efficacy of PRP is the
timing of delivery.119 The vast majority of previous PRP-
augmented rotator cuff studies have delivered PRP at the
time of surgical repair.20,114 After activation, platelets
release growth factors almost immediately with total
elution within 1 hour, and the half-life of growth factors
is a matter of minutes to hours.93 Furthermore, each cyto-
kine will contribute differently to the repair process at dif-
ferent time points after injury or repair. For example,
PDGFs may have a more pronounced effect on tendon cel-
lular maturation and biomechanical strength when deliv-
ered at 1 week compared with earlier delivery.22 Hence, the
timing for PRP delivery remains an important consider-
ation for optimizing tendon healing and should be consid-
ered in future studies. To enable meaningful assessment of
the effectiveness of PRP across studies, researchers must
take care to characterize the composition of biologic com-
pounds and standardize delivery protocols. Key areas for
TABLE 2
Summary of Level 1 Studies With Minimum 6-Month Follow-up Evaluating the Role of PRP
to Augment Surgical Rotator Cuff Repaira
Authors
No. of
Patients PRP Formulation
Surgical
Technique
Outcome
Measurements Follow-up Results
Wang et al140 60 US-guided PRP 7 and 14
days postsurgery
Double row Oxford, SF12,
QDASH
scores, MRI
6, 12, 16
wk
No differences
Malavolta et al81 54 10 mL of liquid PRP (1.5
mL of autologous
thrombin and 0.8 mL of
10% CaCl2)
Single row Constant,
UCLA
scores
3, 6, 12,
24 mo
No differences
Antuna et al5 28 P-PRP gel (injectable
PRP—vivostat system)
Single row VAS, Constant
score, MRI
1 y No differences
Ruiz-Moneo
et al117
63 P-PRP gel (injectable
PRP—PRGF Endoret
system)
Double row UCLA score,
MRI
1 y No differences
Weber et al141 60 P-PRP fibrin (suturable
PRP—Cascade system)
Single row ROM, UCLA
score, SST
score, VAS
3, 6, 9, 12
mo
No differences
Jo et al65 48 Suturable PRP (COBE
spectra system)
Transosseous
equivalent
MRI/CTA,
ROM,
clinical
outcome
scores
1 y Improved structural outcomes in
PRP group, but no differences in
clinical outcomes except overall
shoulder function at 1 y.
Gumina et al53 40 P-PRP gel (suturable
PRP—RegenKit–THT
system)
Single row Constant,
MRI, and
SST score
13 mo No differences in function but better
repair integrity in PRP group.
Rodeo et al114 79 P-PRP fibrin (moderate to
low platelet
concentration;
suturable PRP—
Cascade system)
Single or
double row/
transosseous
equivalent
ASES score,
Doppler US
1 y Better in control group
Randelli et al111 53 L-PRP (high leukocyte
and platelet
concentrations;
injectable PRP—
Plasmax system)
Single row SST score,
UCLA
score,
Constant
score, SER
3, 6, 12,
24 mo
No differences
Castricini et al20 88 P-PRP fibrin (moderate to
low platelet
concentrations;
suturable PRP—
cascade system)
Double row Constant
score, MRI
16 mo No differences
aASES, American Shoulder and Elbow Surgeons; CTA, computed tomography arthrography; L-PRP, leucocyte-rich platelet-rich plasma;
MRI, magnetic resonance imaging; PRP, platelet-rich plasma; P-PRP, pure platelet-rich plasma; QDASH, quick Disability of the Arm,
Shoulder, and Hand; ROM, range of motion; SER, strength in external rotation; SF12, Short Form–12; SST, simple shoulder test; UCLA,
University of California, Los Angeles; US, ultrasound; VAS, visual analog scale.
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future research and challenges facing widespread imple-
mentation of PRP preparations to treat rotator cuff injuries
are summarized in Table 3.
Mesenchymal Stem Cells
MSCs hold great promise for rotator cuff tissue engineering
because of their capacity to differentiate into bone, carti-
lage, and tendon cells and their ability to support a regen-
erative microenvironment through the release of trophic
factors while tempering immune responses.98 As such,
MSC-based therapies may facilitate rotator cuff healing
by differentiating into tenocytes or osteoblasts, by recruit-
ing and stimulating progenitors, and by reducing inflam-
mation. Studies demonstrating decreased resident MSC
numbers in patients with rotator cuff tears provide further
rationale for supplementing healing rotator cuff tendons
with exogenous MSCs.59 It is not clear whether patients
with low resident progenitors are predisposed to rotator
cuff tears or whether this reflects an exhaustion of the local
progenitor pool after attempts at healing.
Human MSCs have been reported to be manipulated to
differentiate into a tenogenic lineage and produce tendon
tissue when exposed to the appropriate stimuli in culture.83
Factors known to regulate the differentiation of MSCs into
tenocytes include TGFb3, scleraxis, BMPs, prostaglandin
E, and the stimulus of a mechanical load.24 Cells can be
used alone or in combination with biocompatible scaffolds
and growth factors, which are delivered intraoperatively to
the site of tissue damage. A number of studies in animal
models have evaluated the use of MSCs to improve healing
after rotator cuff repair.51,71,146 Although a number of clin-
ical studies have evaluated MSCs in the context of rotator
cuff repair, no level 1 studies have yet been performed.35,58
MSC Sources and Purification. Numerous sources of
MSCs, methods of cell purification, and formats of delivery
are now available and have been summarized in part 1 of
this series.76 Although the ideal preparation and method of
delivery of MSCs is not clear, it is important to appreciate
the potential advantages and pitfalls of each.
Bone marrow and fat remain the most popular source of
MSCs in studies evaluating rotator cuff regeneration.
However, a number of studies have explored sources of
MSCs within the shoulder in an attempt to avoid the
requirement for a distant surgical procedure (eg, pelvic
bone marrow aspirate or lipoaspirate). Beitzel et al11
demonstrated that arthroscopic bone marrow aspiration
from the proximal humerus consistently yields reliable con-
centrations of MSCs. Utsunomiya et al136 isolated and
characterized MSCs from 4 shoulder tissues during arthro-
scopic rotator cuff repair: synovium of glenohumeral joint,
subacromial bursa, rotator cuff tendon, and enthesis at
greater tuberosity. They concluded that the subacromial
bursa may be a good candidate for the source of MSCs in
rotator cuff surgery. Song et al129 isolatedMSCs from bursa
tissue associated with rotator cuff tendons and confirmed
their capacity for multilineage differentiation in vitro and
in vivo. Unfortunately, the limited number of cells available
from these sources has so far restricted their application in
a nonexpanded format.96
Preclinical Studies. The use of MSCs to enhance tendon
regeneration has been examined in several animal models
of tendon injury, although the number specifically evaluat-
ing their role in rotator cuff tendon repair is limited.50,146 In
a case-control study on 80 rats, Gulotta et al50 reported that
the injection of bonemarrow–derivedMSCs (BMSCs) at the
time of rotator cuff repair did not improve the histologic or
biomechanical properties of the tendon attachment site.
The authors concluded that concomitant delivery of cellular
and/or molecular signals to induce appropriate differentia-
tion of the transplanted cells was probably required. Kim
et al71 compared the use of a tridimensional open-cell poly-
lactic acid scaffold with and without BMSCs as an augment
to rotator cuff repair. They reported the persistence of
implanted cells to at least 6 weeks, with BMSC implanted
repairs having greater type I collagen expression when
compared with acellular controls. Yokoya et al146 reported
improved mechanical strength and an increase in type I
collagen production at 4 months in rat rotator cuff defects
managed with a polyglycolic acid scaffold seeded with
BMSCs also in a rat model.
Clinical Studies. Only 2 studies have evaluated the
application of MSCs in rotator cuff surgery. Ellera Gomes
et al35 investigated the effects of bone marrowmononuclear
TABLE 3
Use of Platelet-Rich Plasma for Rotator Cuff Healinga
Targeted Areas for Future Research Barriers to Advancement and Implementation
 Which factors are central to regenerative effects of PRP in
rotator cuff healing?
 Most effective platelet and leukocyte counts for rotator cuff
healing
 Multicenter RCTs evaluating the above
 Most effective method of PRP activation for rotator cuff healing
 Optimal timing of delivery
 Optimal dosing (including repeated dosing)
 Does tear location (tendon substance/avulsion) influence most
effective PRP preparation or timing of delivery?
 Potential for PRP used in combination with GFs and MSCs
 Models of rotator cuff tendon injury with sufficiently sensitive
imaging to detect differences in clinical outcomes
 Lack of standardization in PRP preparation precluding
comparison
 Lack of sufficient experimental details in published reports
aGFs, growth factors; MSCs, mesenchymal stem cells; PRP, platelet-rich plasma; RCT, randomized controlled trial.
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cells (BMMCs) on rotator cuff healing in 14 patients with
complete tears. Although no control group was used in this
study, the authors concluded that delivery of BMMCs was
safe and had potential to enhance rotator cuff regenera-
tion. In a case-control study of 45 patients, Hernigou
et al58 reported significant improvement in healing out-
comes at 10 years in patients receiving MSCs as an
adjunct therapy in standard of care rotator cuff repair.
In this study, injection of MSC as an adjunctive therapy
enhanced the healing rate and improved the quality of the
repaired surface as determined by ultrasound and mag-
netic resonance imaging (MRI).
Microfracture. Microfracture of the greater tuberosity,
just lateral to the site of rotator cuff repair, results in a
large clot containing MSCs, platelets, and growth factors
that has hence been referred to as a ‘‘crimson duvet.’’127
Microfracture awls are utilized to perforate into the cancel-
lous bone enabling marrow to ooze out to cover the rotator
cuff repair. This clot acts a reservoir of growth factors and a
surface to guide the migration and proliferation of progeni-
tor cells.84 This method is inexpensive and technically
straightforward, but as with nonpurified MSC prepara-
tions, its efficacy may be limited by cell heterogeneity inhi-
biting MSC differentiation.97
In a randomized controlled trial of 57 patients under-
going arthroscopic rotator cuff repair, Osti et al104
reported that microfracture at the rotator cuff footprint
resulted in reduced short-term pain. However, augmen-
tation with microfracture did not result in significantly
different longer term outcomes, clinically or at imaging,
compared with traditional rotator cuff repair.104 In a
further prospective randomized study of 80 patients eval-
uating greater tuberosity microfracture augmentation of
rotator cuff repair, Milano et al88 found no significant dif-
ference between groups on MRI analysis of structural
integrity. However, patients receiving microfracture for
large tears demonstrated significantly improved healing
rates.
Gene Therapy. Gene therapy involves the insertion of
genetic material into a target cell so as to manipulate the
behavior of that cell.79 Understanding the expression pro-
file of growth factors central to the development of the nor-
mal enthesis in development might reveal candidate
cytokines that could be used to augment the tendon repair
site.39 The majority of growth factors are short-lived within
the site of injury, thus requiring repeated dosing if direct
delivery is to be effective.79 A key advantage of gene ther-
apy is the potential for continuous production of the growth
factor or cytokine by cells that become established within
the wound.79 In ex vivo gene therapy, cells are harvested,
cultured, and transduced with the vector in culture prior to
reimplantation.138 Gene therapy approaches in rotator cuff
repair have been used to manipulate expression of scler-
axis, BMP13, and platelet-derived growth factor receptor–
b (PDGFRb).51,52,135
Scleraxis is a transcription factor necessary for tenogen-
esis within the developing enthesis.68 In a rat model of
rotator cuff repair, BMSCs transduced with adenoviral-
mediated scleraxis were applied to the tendon-bone repair
site.51 Animals receiving MSCs transduced with scleraxis
had greater stiffness and stress to failure and a signifi-
cantly increased load to failure at 4 weeks after repair.51
Although there were no histological differences between
experimental and control groups at 2 weeks after repair,
the insertion site of the scleraxis group had more fibrocar-
tilage that more closely resembled the native tendon-bone
insertion site. Also in a rat model, the same group examined
the ability of BMSCs transduced with human BMP13 to
improve rotator cuff healing in a rat model.52 There were
no differences in new cartilage formation, collagen fiber
organization, or biomechanical strength at the repair site
between experimental and control groups at 4 weeks after
repair.
Uggen et al135 transduced rat tendon fibroblasts with
IGF1 or PDGFRb via retroviral vectors. These cells were
expanded in culture and delivered on a bioabsorbable scaf-
fold over a supraspinatus repair. Animals that received the
PDGFRb overexpressing cells showed near complete
restoration of the tendon, significantly better than suture
repair alone.135 These data indicate that it may be possible
to manipulate and deliver growth factors to promote a
regenerative response.
Targeted Areas for Future Research and Barriers to
Advancement and Implementation. A key area of future
research must be to identify the mechanisms by which the
native cells within the rotator cuff tendon and surrounding
tissues contribute to rotator cuff healing and the formation
of scar tissue. There has been an increasing appreciation
that MSCs can become activated myofibroblasts, contribut-
ing to tissue fibrosis after severe or repetitive injury.75 The
identity of cells contributing to repair of normal enthesis
prenatally and the identity of cells contributing to scar for-
mation after injury have yet to be identified. Modern mouse
genetic tools now facilitate cellular fate mapping in a
diverse range of biological processes.112 The Cre/loxP sys-
tem, which is widely used for this purpose, employs the
gene for bacterial Cre recombinase (causes recombination:
an enzyme that can perform site-specific knockdown of
genes), which is linked to a cell- or lineage-specific promoter
prior to incorporation in the genome of a transgenic
mouse.49 Studies are urgently required that utilize fate
mapping to establish the role of resident cells in the
response to rotator cuff injury and repair.
The vast majority of studies exploring muscle, bone, and
cartilage regeneration withMSCs in which the fate of deliv-
ered MSCs have been assessed have reported that only a
fraction of the delivered cells can be found at the site of
repair beyond the acute phase.41,94 The majority of authors
have concluded that one of the many trophic factors
released by MSCs must be responsible for their therapeutic
effect, but no definitive studies have identified this elusive
factor.41,94 It is not clear whether the presence of MSCs is
required for the therapeutic effect or whether the delivery
of the responsible factor(s) in isolation could be a further
therapy. Approaches to address this question may include
the delivery of fluorescently labeled cells to delineate their
fate and the delivery of MSCs with the systematic knock-
down of potential target molecules.
For therapies involving the application of MSCs; the
ideal stem cell source, preparation, and number; and the
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optimal timing of delivery remains largely unexplored but
is critical to the translation of this technology. One poten-
tial advantage of allogeneic over autologous cells is the pos-
sibility of their use as an ‘‘off-the-shelf’’ therapeutic agent,
avoiding the need for bone marrow aspiration and tissue
culture delays before treatment. Furthermore, some stud-
ies indicate that the function of MSCs in patients with
advanced age or significant comorbidities is impaired
(including impaired differentiation potential and senes-
cence).66 Allogeneic cells may therefore be of particular
benefit in the elderly or those with multiple comorbidities.
Further studies are required to establish the most favor-
able site of MSC harvest and whether allogeneic or auto-
logous cells are favorable.
It is not clear from the limited studies to date what the
optimum number of cells for each indication is or whether
there is a critical number of cells to exert therapeutic ben-
efit.32 It is intuitive that the optimal number of cells will
vary relative to the size of the rotator cuff defect, the cell
type used, and the particular region in need of repair. MSCs
can be exposed to differentiation factors in culture to begin
the process of tenocyte differentiation prior to implanta-
tion.80 Future studies should establish whether this is ben-
eficial to the delivery of naive MSCs. Similarly, growth
factors that induce directed differentiation or promote a
regenerative microenvironment can be delivered simulta-
neously. The optimal combinations of MSC and growth fac-
tors for rotator cuff repair should be a focus of future
research efforts. Potential off-target effects of these factors
on local cell populations should be explored, as well as
adverse systemic effects.
Having established that a reservoir of MSCs resides in
almost every tissue,29,97 the question of whether therapeu-
tic strategies could be employed to ‘‘recruit’’ or accelerate
the regeneration capacity of resident MSCs after injury
should be considered. The ‘‘activation’’ of adult stem cells
is known to be regulated, in part, by their neighboring cells;
manipulation of this communication through the local
infiltration of growth factors or molecules integral to this
communication may represent such a therapeutic
strategy.96
In the future, it may be possible to use alternative
sources of stem cells such as induced pluripotent stem (iPS)
cells, embryonic stem cells (ESCs), or other recently iden-
tified adult stem cell populations. MSCs have been gener-
ated from both iPS cells and ESCs, raising the possibility of
direct delivery of these more primitive populations.26
Tendon-derived stem/progenitor cells (TSPCs) can differ-
entiate, form tendon-like tissue, and have the ability to
synthesize tendon extracellular matrix.12 However, no
studies using TSPCs to augment rotator cuff repair have
so far been reported. The native origin of these cells is
interesting given the presumed perivascular origin of
mesenchymal progenitors in organs and the avascular
nature of tendons.29 A population of muscle-derived stem
cells (MDSCs) has been derived using a modification of the
preplate technique that uses the adhesion characteristics of
the cells to collagen-coated flasks.47 In vivo studies have
demonstrated that MDSCs differentiate into multiple
lineages, self-renew, and regenerate bone, cartilage, mus-
cle, blood, and cardiac tissue.18 MDSCs injected into
supraspinatus tendons of athymic rats incorporated into
host tissue with a morphology comparable to resident ten-
don fibers.108 However, the ability of MDSCs to regenerate
tendon after injury remains unclear. Keys areas for future
research and critical barriers to advancement of MSCs for
rotator cuff healing are summarized in Table 4.
Patches
Augmentation of rotator cuff repair with patches can result
in improved clinical outcomes compared with nonaug-
mented repairs.8,36 Patches can be nondegradable, based
on xenogeneic or allogeneic extracellular matrix (ECM)
constructs, or degradable scaffolds that can be combined
with stem cells, matrix proteins, and growth factors. There
TABLE 4
Use of Mesenchymal Stem Cells for Rotator Cuff Healinga
Targeted Areas for Future Research Barriers to Advancement and Implementation
 Identify stem cells responsible for regeneration and scar tissue
formation after rotator cuff tears (murine lineage tracing studies)
 Identify mechanisms by fate decision (regeneration vs fibrosis) occur
after rotator cuff injury
 Optimal MSC source (bone marrow, adipose tissue)
 Optimal method of isolation (culture derived/FACS)
 Optimal dosing of MSCs (critical number)
 Is predifferentiation beneficial (tenocyte or osteoblast)?
 Optimal timing of delivery
 Optimal dosing (including repeated dosing)
 Does tear location (tendon substance/avulsion) influence
predifferentiation, timing of delivery, or codelivery with GFs?
 Optimal carrier for exogenous MSCs
 Understanding mechanisms by which local MSCs can be recruited
and activated
 Safety and efficacy of gene therapy
 Models of rotator cuff tendon injury with sufficiently
sensitive imaging to detect differences in clinical outcomes
 Lack of standardization in MSC preparation
 Lack of sufficient experimental detail in published reports
aFACS, fluorescence-activated cell sorting; GFs, growth factors; MSCs, mesenchymal stem cells.
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is currently no clear consensus as to what is the most effi-
cacious patch strategy and whether their use is safe in the
long term. Augmentation with nondegradable structures
aims to provide permanent mechanical support to facilitate
self-healing. Nondegradable patches require good strength
and tissue compatibility and have been made from materi-
als, including polycarbonate polyurethane, polytetrafluoro-
ethylene, and polyester. To encourage tissue ingrowth,
these materials are typically processed into foam or felt
allowing cells to penetrate the surface and incorporate.
Concerns include the occurrence of persistent infections
and loss of integrity over time, where fragmentation may
lead to mechanical failure or chronic inflammation. Studies
evaluating restoration of massive rotator cuff defects with
synthetic grafts have reported significant short-term
improvements in pain and function.7,99
ECM-based scaffolds aim to provide a temporary,
collagen-based matrix to facilitate integration of local
cells. ECM-based patches extracted from porcine intest-
inal mucosa (SIS), porcine dermis, human fascia, and
human dermis are available. Despite performing well as
substrates for tendon-derived cells in vitro, in vivo studies
have produced conflicting results.109,149 Concerns related
to ECM-derived scaffolds include poor suture retention,
limited mechanical properties, and toughness.25,149
Traces of DNA and cellular content have also been found
in some ECM-derived patches, raising a theoretical risk of
disease transmission or an adverse inflammatory
response.48 Despite these issues, many ECM-derived
patches are approved by the Food and Drug Administra-
tion and are commercially available. Porcine dermal col-
lagen and SIS have both been used effectively to provide
strength and support when connective tissues have been
lost.105,116,124 However, clinical data supporting their use
for rotator cuff augmentation in humans are limited.102
Using a porcine collagen dermal patch, Badhe et al8
demonstrated significant functional improvements after
augmented rotator cuff repair in a study of 10 patients,
with 80% graft patency on MRI at a mean 4.5 years. Soler
et al128 investigated the ability of porcine dermal collagen
to serve as an augmentation material in massive rotator
cuff repair. Ultimately, all patients demonstrated signs
and symptoms of a recurrent tear despite this treatment.
Sclamberg et al122 found that SIS was ineffective at rein-
forcing large and massive rotator cuff tears, with 10 of 11
patients having recurrent defects within 6 months.
Furthermore, Iannotti et al60 recommended against using
porcine SIS for augmentation of large and massive rotator
cuff tears after finding reduced postoperative functional
scores in a randomized controlled study. Barber et al9 per-
formed a randomized controlled trial to compare arthro-
scopic single-row repair with or without acellular human
dermal patch (commonly known as Graftjacket) augmen-
tation. Augmented repairs had significantly greater
American Shoulder and Elbow Surgeons (ASES) and Con-
stant scores then nonaugmented repairs at 24 months. On
MRI at 14.5 months, 85% of patients in the augmentation
group had intact repairs compared with 40% in the control
group. Unfortunately, studies funded by different compa-
nies have produced contradictory results and large, long-
term, and impartial comparative trials are required. Overall,
the efficacy and safety of using ECM-derived patches
remains uncertain.
Degradable synthetic scaffolds provide a nonperma-
nent support for intrinsic or implanted progenitors while
addressing issues relating to cost and potential disease
transmission relating to ECM-based scaffolds.54 The non-
permanent support aims to encourage cellular ingrowth
and tendon self-healing. Degradable polyesters include
poly-L-lactic acid, poly lactic-co-glycolic acid, polycaprolac-
tone, and polydioxanon.54 The material can be used as a
plain synthetic sheet or by fabricating patterned struc-
tures to mimic the orientation of collagen fibrils.90,145
Stem cells, matrix proteins, and growth factors can be
loaded and delivered within the patch. Despite promising
preliminary results, there are some concerns about the
persistence of polymer degradation products.87 Further
issues of electrospun materials are their low mechanical
properties, which frequently requires reinforcement with
more robust structures and the small size of their pores
limiting cell migration into the scaffold and tissue
ingrowth.90 In addition, the hydrophobic character of
polyesters can contribute to poor initial seeding density
of codelivered cells.42
A polyglycolic acid sheet cultured with autologous
BMSCs has been used to repair resected infraspinatus ten-
dons in rabbits.145 An increased production of type I col-
lagen and an increment of the mechanical strength was
seen 4 months after repair as compared with both a non-
augmented control and a nonloaded scaffold group. Kim
et al71 harvested and expanded BMSCs from rabbits prior
to seeding on a polylactic acid scaffold. This study showed
that MSCs survived for 6 weeks within the scaffold, and
type I collagen expression was increased in the scaffold
with BMSCs. Shen et al126 used a knitted silk-collagen scaf-
fold loaded with allogeneic Achilles tendon stem cells to
augment a rotator cuff repair in rabbits. Increased fibro-
blastic cell ingrowth and reduced infiltration of lympho-
cytes were observed at the repair site at 8 weeks, while
structural and mechanical proprieties were improved at
12 weeks as compared with controls.
Several studies have focused on re-creating the complex
tendon-bone interface.130 Spalazzi et al130 showed that
fibroblasts and osteoblasts initially confined to soft tissue
and bone formation areas in a triphasic scaffold migrated
into an intermediate layer leading to increased production
of a type I collagen matrix. Moffat et al91 investigated the
use of a biphasic nanofiber scaffold containing mineralized
and nonmineralized regions to augment rotator cuff repairs
in rats. They demonstrated viable chondrocytes with col-
lagen/proteoglycan matrix in both phases of the scaffold.
Rats repaired with the scaffold showed an organized
fibrocartilage-like transition zone.91
Targeted Areas for Future Research. The technology of
patches has greatly developed in recent years, but this has
not yet translated into functional improvements for
patients.54 The concept of patches as a static, mechanical
support that is biologically inactive is now waning. Newer
generations of predominantly degradable synthetic
patches are emerging that seek to combine targeted
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mechanical properties with stem cells or growth factors.54
These patches are designed to completely absorb in a
timely manner so as to minimize risk of infection. How-
ever, this strategy has yet to be proven in clinical trials,
and future research must concentrate on comparative
clinical trials of the commercially available patches. While
industry involvement is integral to the development of
patches, evaluative studies must take place in more neu-
tral, academic settings.
A recurring theme throughout the literature is concern
regarding potential adverse effects of synthetic degradation
products.87 Toxicities appear to vary between polymers,
and there are currently no data relating to the shoulder.
Future studies should evaluate the release of degradation
products until the implant is completely degraded to defi-
nitively establish whether levels of acidic products released
remain within safe levels. Key areas for future research
and critical barriers to advancement of patches in the
repair of rotator tears are summarized in Table 5.
Biologic Strategies to Augment Healing
in Rotator Cuff Muscle
Muscle atrophy and fatty degeneration are recognized fac-
tors implicated in rotator cuff repair failure, yet there is a
paucity of work dedicated to addressing this process. Mus-
cle atrophy and fatty degeneration decrease the compliance
of the muscle-tendon unit and lead to rotator cuff retraction
and increased tension at the repair site.45
Anabolic Steroids. Anabolic-androgenic steroids are syn-
thetic derivatives of testosterone that act on androgenic
receptors to exert their anabolic effects.37 At supraphysio-
logic doses, they increase muscle size and strength, pro-
mote collagen synthesis, and increase bone mineral
density.37 In a rabbit model of chronic rotator cuff tears,
Gerber et al44 demonstrated that administration of
nandrolone decanoate reduced fatty infiltration within the
supraspinatus muscle and prevented muscle impairment
resulting from myotendinous retraction. While anabolic-
androgenic steroids represent a promising strategy to
temper muscle deterioration after tendon tear, they are
recognized to have potentially serious adverse effects.132
As immunosuppressants, steroids potentially increase sus-
ceptibility to infection, and the long-term health risk of
their use in not known. Furthermore, anabolic-androgenic
steroids are considered as performance-enhancing drugs,
and their use is banned in athletic competitions. Further
studies are required to establish whether anabolic-
androgenic steroids have a role in rotator cuff healing.
Targeted Areas for Future Research. The inherent myo-
genicity of MSCs makes them an attractive substrate for
skeletal muscle regeneration or augmentation, and MSCs
have been demonstrated to differentiate into myotubes and
regenerate skeletal muscle after cardiotoxin injury.29
Furthermore, they release a host of trophic factors known
to contribute to tissue regeneration. In addition to their
proangiogenic effects, MSCs reduce hypoxia-driven angio-
genesis.64 It is conceivable that MSCs isolated from lipoas-
pirate at the time of rotator cuff surgery could be delivered
during repair to improve postoperative muscle function and
compliance. Conversely, this strategy could be used in a
staged procedure to treat atrophic muscle prior to repair,
improving myotendinous compliance and diminishing ten-
sion at the repair site. Key areas for future research and
critical barriers to advancement of biologics in the regen-
eration of rotator cuff muscle are summarized in Table 6.
CONCLUSION
Rotator cuff tears often result in considerable morbidity
and extended periods of sporting absence. Recent advances
in understanding the pathophysiology of rotator cuff
TABLE 5
Use of Patches for Rotator Cuff Healing
Targeted Areas for Future Research Barriers to Advancement and Implementation
 Impartial comparative trials of commercially available studies
 Long-term studies of degradable patches to evaluate
safety of degradation products
 Models of rotator cuff tendon injury with sufficiently sensitive
imaging to detect differences in clinical outcomes
 Lack of sufficient experimental detail in published reports
TABLE 6
Use of Biologics in Rotator Cuff Muscle Regenerationa
Targeted Areas for Future Research Barriers to Advancement and Implementation
 Identify source of profibrotic and proadipogenic cells in fatty
degeneration of the rotator cuff after injury
 Role for exogenous MSC implantation in improving muscle
compliance while reducing fatty infiltration and fibrosis
 Strategies to reduce fibrosis (eg, targeting TGFb pathway)
 Strategies to reduce fatty infiltration
 Preparation, timing, and dosing of biologic therapy
 Models of rotator cuff tendon injury with sufficiently sensitive
imaging to detect differences in clinical outcomes
 Some therapies considered as performance enhancing by
doping authorities
 Lack of sufficient experimental detail in published reports
aMSC, mesenchymal stem cell; TGFb, transforming growth factor–b.
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healing and the role of growth factors and progenitors have
highlighted the potential role for biologics to augment sur-
gical repair. Animal studies indicate that delivery or mod-
ulation of growth factors may provide a useful way of
improving the biology of rotator cuff healing, although
human studies to support this are currently lacking. The
use of PRP in a number of recent randomized controlled
trials of surgical rotator cuff repair has not met the expec-
tations raised by in vitro studies. Clinical studies evaluat-
ing the use of MSCs in surgical rotator cuff repair show
great promise, but randomized clinical trials are lacking
and considerable work is required to establish the true
mechanism by which these cells contribute to rotator cuff
regeneration. With all the biologic approaches to rotator
cuff repair discussed, considerable variation in experimen-
tal techniques and methods of production have so far lim-
ited meaningful interpretation of the literature. Currently,
there exists a lack of consensus on the optimal preparation,
source, delivery method, and dosing of biologics for ortho-
paedic applications. The problem is exacerbated by a lack of
sufficient experimental detail in many publications, which
impairs readers’ ability to evaluate the quality of results or
compare results across studies. A collaborative approach to
biologics research is required with standardization of tech-
niques, guidelines for the minimum reporting of experi-
mental details, and large multicenter randomized
controlled studies.
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